In light of the 2 negative bevacizumab trials for up-front GBM, how do you feel about the future of bevacizumab in GBM?

At the 2010 ASTRO meeting, Dr Inder Verma of the Salk Institute gave a very nice keynote address talking about his work using a mouse model of GBM where the GBM cells themselves can morph into vessels as needed, with no expectation of response to anti-VEGF therapy. The work was published a while bac...